The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions. This gene is unusual in that it codes for two distinct proteins: a small mitochondrial protein, p8
Introduction
The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia (T-PLL) and with a related condition, ataxia telangiectasia clonal proliferation (ATCP), so far described only in patients suering from ataxia telangiectasia (AT) (Stern et al., 1993; Fisch et al., 1993; Thick et al., 1994) . The presence of similar translocations in ATCP and in T-PLL supports the view that these translocations play a role in the earliest stages of the disease. The six characterized t(X;14) breakpoints occurred 5' to or within the MTCP1 gene (Stern et al., 1993; Fisch et al., 1993; Thick et al., 1994; Madani et al., 1996) . MTCP1 is located on chromosome Xq28, approximately 70 kb telomeric to the Factor VIII gene. It is placed head-to-head to the c6.1A gene and shares with it a 5' G/C-rich region which presumably acts as a promoter sequence for both genes. MTCP1 genomic organization includes seven exons spread over approximately 10 kb. Alternative splicing generates transcripts encoding two entirely distinct proteins, which is highly unusual in vertebrates. The ®rst class of mRNAs (named A transcripts) is ubiquitous and moderately abundant, and is generated by splicing exon I directly to exon VI. A short open reading frame overlapping exons VI and VII, codes for a small protein of 8 kD (p8 MTCP1 ) (Soulier et al., 1994) located in the mitochondria (Madani et al., 1995) and highly expressed in T-cell proliferations with t(X;14) (Stern et al., 1993; Fisch et al., 1993; Soulier et al., 1994; Thick et al., 1994; Madani et al., 1996) . The second class of mRNAs (named B1 transcript) is approximately 2 kb long and includes the seven exons of the gene. Its very low abundance in normal tissues is speculatively due to the divergent splicing acceptor site of exon II (Stern et al., 1993) . A 321 nt open reading frame encompassing exons II to IV codes for a 13 kD protein (p13 MTCP1 ) (Madani et al., 1996) . This second protein shares signi®cant homology with the product of TCL1, p14 TCL1 (Fu et al., 1994) . TCL1 has been identi®ed as the 14q32.1 candidate oncogene implicated in approximately 70% of the translocations associated with both T-PLL and ATCP (Matutes et al., 1991; Taylor et al., 1996) . Expression of p13
MTCP1 has so far been demonstrated only in t(X;14)-associated Tcell proliferations (Madani et al., 1996) . The homology of p13 MTCP1 with p14 TCL1 and its restricted expression to t(X;14)-associated proliferations is highly suggestive of an oncogenic role for p13
MTCP1
. Screening approximately 3610 6 recombinant l phages of a T-cell line SUPT1 cDNA library allowed us to isolate a single B1 cDNA clone, representing transcripts barely detectable by Northern blot in polyA-enriched RNA from a large collection of tissues and cell lines (Stern et al., 1993) . Furthermore, p13
remains undetectable in normal tissues (Madani et al., 1996) , complicating our task to unravel the physiological role of this protein and the mechanism of regulation of the expression of p8
and p13
-encoding transcripts. In an analysis of MTCP1 transcription by PCR ampli®cation after reverse transcription, products compatible with B transcripts were demonstrated in T-cell proliferations bearing a t(X;14) translocation . However, such an assay is inappropriate to identify undescribed transcripts.
Here, we took advantage of the identi®cation of two patients with t(X;14)-associated T-PLLs from whom sucient biological material was available. Breakpoints were characterized and correlated with MTCP1 transcription.
Results

Characterization of two t(X;14) translocations in T-PLL
We screened for t(X;14) translocations in T-PLLs recruited from French hematological centers by cytogenetic, genomic and biochemical analyses. In addition to the two initial cases (Civ and Dol), two additional t(X;14)-associated T-PLLs were detected, one previously reported (Lec) (Madani et al., 1996) and a new case (Jun). The MTCP1 gene was studied by standard Southern blot techniques using dierent MTCP1 probes and several restriction digests, allowing the analysis of approximately 50 kb 5' to and within MTCP1.
Analysis of DNA from the T-PLL`Jun' revealed a rearranged MTCP1 gene. On a BamHI digest, a rearranged 23 kb band was detected in addition to the 14 kb germline band using the 0.4XX probe (Figure 1a and b) . Using the same probe on an EcoRI digest, a rearranged 6 kb band was detected in addition to the 5 kb germline band (data not shown). On the BamHI digest, probe 1.5RR, located 5' to 0.4XX, detected the same germline band, but a dierent 8 kb rearranged fragment. Therefore, the breakpoint has occurred within the EcoRI ± XhoI region located 5' to exon I, where the Civ T-PLL breakpoint has been previously mapped (Stern et al., 1993) . The karyotype of the Jun T-PLL con®rmed the presence of a t(X;14) translocation (data not shown).
A previous analysis of Lec T-PLL DNA showed that a translocation had occurred between the 1.0XH and the 4.5RB fragments (Madani et al., 1996) . On a BamHI digest, probe 0.9HH, located 3' to exon I, revealed two non-germline bands of 10 and 16 kb in addition to the 14 kb germline band, showing that the translocation event had occurred within this 0.9 kb HindIII fragment (Figure 1a and b) . Probes derived from the TCRA Ja region were used and the EcoRI ± SacI fragment containing the Ja58 and Ja59 segments revealed a band comigrating with the 10 kb rearranged fragment detected with the 4.5RB probe. To precisely map this breakpoint, the breakpoint region was ampli®ed using a series of primers located in the 0.9HH fragment (including primer #1896) and in the Ja58 and Ja59 segments. The combination of the primers #1896 and Ja58 ampli®ed a fragment of approximately 400 bp which was sub-cloned and sequenced ( Figure 1c ). The translocation breakpoint had occurred 314 bp 3' to the end of MTCP1 exon I and 5' to the Ja58 segment deleting the ®ve nucleotides following the heptamer recombination signal sequence. Nine nucleotides at the junction without a genomic template were probably generated by the N diversity mechanism. The translocation event in Lec T-PLL dissociated most of MTCP1 gene (exons II-VII) from its promoter upstream to exon I.
Western blot analysis of Jun and Lec leukemic proteins showed a detectable level of p13 MTCP1 ( Figure   2 ), consistent with our previous observations (Madani et al., 1996) . This demonstrated that these leukemic cells expressed MTCP1 transcripts containing exons II, III and IV, which are coding for p13
MTCP1
. These transcripts were then analysed in both patients.
MTCP1 transcriptional analysis
The transcription initiation site was ®rst de®ned by the RNAse protection assay. Transcription of MTCP1 in Jun leukemic RNAs was analysed using an antisense probe derived from a genomic fragment including exon II and 586 bp upstream to it. Major bands of approximately 150 nt and 700 nt were detected which corresponded to the sizes of normally spliced exon II and of unspliced transcripts, respectively ( Figure 3a) . A weaker 700 nt band was detected in both thymus and PBL RNA, and the 150 nt band was present only in thymus RNA and at a low level. Transcription of MTCP1 B transcripts in Jun T-PLL was then con®rmed by RT ± PCR. Two bands of 712 and 442 bp were detected by semi quantitative assay for B transcripts, corresponding to the use of two previously described alternative splicing donor sites in exon I (Stern et al., 1993) . Both bands were found at a much higher level in Jun RNA compared to normal PBL RNA (Figure 3b ). Using the same antisense probe, a major band of approximately 400 nt was protected by Lec RNA but not by PBL, thymic or Jun RNA (data not shown). To precisely de®ne these transcripts, an intronic XbaI ± HindIII fragment corresponding to bases 7586 to 7150 from exon II was used as an antisense probe (Figure 4a) . A major band of approximately 80 nt was protected by Lec T-PLL RNA. This band was absent in normal PBL RNA. Minor bands of approximately 150 nt, accounting for less than 10% of the transcripts, were also visible in Lec RNA.
The initiation site was then searched using the single strand ligation to single strand cDNA (SLIC) method (Dumas et al., 1991) . Using Lec leukemic RNA, two successive anchored PCRs were performed to characterize the 5' origin of the MTCP1 transcripts. A reverse transcription followed by PCR ampli®cation was performed using as a common forward primer the anchor primer, and as speci®c backward primers, the primers SLICVIII, SLICIX and SLICII for priming the reverse transcriptase, the ®rst anchored PCR and the nested PCR, respectively (Figure 4b PCR product corresponded to the 80 bp predicted by RNAse protection assay, taking into account the 48 bp arti®cially added by the SLIC method. Nine out of 10 sequenced subcloned PCR products started within the three adenines at 7229 to 7227 bases from exon II (Figure 4b ).
Discussion
T-cell prolymphocytic leukemia is a rare form of lymphoid malignancy. Unlike other mature T-cell proliferations such as Sezary syndrome, large granular lymphocyte proliferation or peripheral T-cell lymphoma, cytogenetic analyses were crucial in determining the oncogenic events leading to this particular form of leukemia. Inversions of translocations involving one or both chromosomes 14 were found in approximately 70% of T-PLLs (Matutes et al., 1991) . In addition, t(X;14) translocations were found occasionally in TPLLs or related disorders (Taylor et al., 1981; Canki et al., 1983; Dallapiccola et al., 1984; Beatty et al., 1986; Witzig et al., 1986; Goyns et al., 1993) . In this paper, we describe two additional t(X;14) translocations in TPLLs. Together with the previously reported cases, seven such translocations are now characterized at the molecular level. In our series of 21 T-PLLs which was collected without consideration of the cytogenetic status, three cases were associated with a t(X;14)
translocation. An additional t(X;14), associated with a benign T-cell proliferation in an ataxia telangiectasia patient, was also characterized at the molecular level (Stern et al., 1993) . Therefore, this translocation accounts for approximately 10% of T-PLLs and ATCPs, a higher frequency than those observed for most recurrent translocations in acute T-cell lymphoblastic leukemia (Rabbitts, 1994) . Although t(X;14) is a relatively frequent event in T-PLLs, the rarity of the disease probably accounts for the low number of t(X;14) reported in the literature. Although t(14;14), inv(14) and t(X;14) chromosomal rearrangements have been known for decades (for a review see Taylor et al., 1996) , it is only recently that their molecular characterization has led to the identification of the two putative oncogenes located in the 14q32.1 and Xq28 regions. Only a systematic analysis of the 14q32.1 region ®nally led in 1994 to the identi®cation of the TCL1 gene . Conversely, the elucidation of the t(X;14) translocation was complicated by the presence of several genes and coding regions in the vicinity of the breakpoint region. The c6.1A gene was shown to form fusion transcripts with the TCRA gene as a consequence of the translocation, but some of these fusion transcripts were out-of-frame and the breakpoint C Gritti et al location in other patients precluded any possibility of a c6.1A/TCR fusion transcript, thus excluding c6.1A as the candidate oncogene (Fisch et al., 1993; Thick et al., 1994) . Transcription of another gene placed head-tohead from c6.1A, MTCP1/c6.1B, is constantly enhanced in T-cell proliferations with t(X;14) (Fisch et al., 1993; Stern et al., 1993; Thick et al., 1994) . Initial characterization of this gene revealed the unusual feature of potentially coding for two dierent proteins (Stern et al., 1993) . Because considerable increases in both A transcripts (Stern et al., 1993; Fisch et al., 1993; Thick et al., 1994) and the 8 kD product (Soulier et al., 1994) were found in t(X;14)-associated T-PLLs, initial studies focused on this mitochondrial protein (Madani et al., 1995) . However, the identi®cation of the TCL1 gene revealed an unquestionable homology with p13
MTCP1
, the product of the rare MTCP1 B transcript. The development of a RT ± PCR assay for B1 transcripts and a sensitive Western blot assay for p13
MTCP1 (Madani et al., 1996) revealed their presence exclusively in t(X;14) associated T-cell proliferations, strongly arguing for an oncogenic role for p13
. In all tissues and tumor cells tested, B1 transcripts represent at most a minor fraction of the MTCP1 transcripts. It is assumed that the limiting step for the generation of p13
-encoding transcripts is the splicing of exon I onto the exon II acceptor site, which diverges from the consensus motif (Stern et al., 1993) . Whether the use of this acceptor site is positively regulated in some tissues or re¯ects a high transcriptional activity of MTCP1, remains unknown. Another mechanism to generate p13
-encoding transcripts is demonstrated here by the transcriptional analysis of a t(X;14)-associated T-PLL, case Lec, in which the translocation has split the exon I and its promoter region from the coding part of the gene. Analyses of the 5' end of its transcripts by anchored PCR and by RNAse protection assay were consistent with an initiation site located at 229 bp upstream to exon II. No transcription from this initiation site was detected in Jun T-PLL, in thymus and in PBL and no physiological tissue using this promoter region is, as yet, identi®ed. The promoter activity in the presence of a SV40 heterologous enhancer, was searched for using a reporter assay and a weak but consistent activity was found in the dierent cell lines tested (Gritti et al. unpublished data) . Altogether, our data were consistent with the presence of a promoter sequence within MTCP1 intron I, probably positively regulated by the TCRA regulation sequences brought by the translocation event.
Although the demonstration of a MTCP1 alternative promoter gives an additional level of complexity to this gene, it also provides a plausible explanation for its distinctive features. As previously mentioned, p13
and p14
TCL1 proteins share a signi®cant degree of homology (approximately 30% of identity). Interestingly, one can also notice the similarity of the respective contribution of TCL1 exons I to IV and MTCP1 exons II to V to p14 TCL1 and p13
, respectively (see Figure 5a) . Furthermore, the alternative promoter 5' to MTCP1 exon II may indicate a relative autonomy of these four exons toward the entire gene structure. This suggests that TCL1 and MTCP1 genes arose from the duplication of a common ancestral gene. In such a model, one gene copy would have been inserted within an intronic region of another gene coding for the mitochondrial p8 protein (Figure 5b ). During evolution, the speci®c promoter and the polyadenylation signal sequence would have been partially replaced in favor of sequences shared by p8-and p13-encoding transcripts. Because genomic organization of murine and human MTCP1 genes is very similar, this event would have occurred before the mammalian speciation. Among the very few mammalian genes known to code for more than one protein product, the MTS1/INK4a/CDKN2 gene codes for two dierent cell cycle inhibitors, p16
INK4a and p19 ARF , using both alternative promoters and alternative reading frames of common exons (Duro et al., 1995; Quelle et al., 1995) . Alternative coding frames have also been reported in the GH gene (Labarriere et al., 1995) . A dierent strategy is used by the calcitonin/CGRP gene in which alternative splicing leads to two dierent secreted peptides (Amara et al., 1982) . One can hypothesize that the conservation of the complex structure of the MTCP1 gene during evolution relates to its biological function. More comprehensive data on MTCP1 protein products will be needed to address this issue.
Materials and methods
Cells
Patient`Lec' is a 71-year-old woman with a CD3+ CD4+CD8+ T-PLL. Patient`Jun' is a 60-year-old woman with a CD3+CD4+CD8+ T-PLL. Both patients had major lymphocytosis and no history of ataxia telangiectasia. Diagnosis was established according to the French-American-British (FAB) criteria for chronic (mature) leukemia (Bennett et al., 1989) .
DNA analysis
High molecular weight DNA was extracted from leukemic samples, digested by BamHI and SacI restriction enzymes and the resulting fragments were separated according to size by electrophoresis through a 0.8% agarose gel. After alkaline transfer on N + Hybond membranes (Amersham), samples were hybridized to 32 P-radiolabeled probes (Stern et al., 1993) . Probes are represented on Figure 1a . Fragments 1.5RR, 0.4XX, and 0.9HH probing the MTCP1 gene were used, as well as the EcoRI ± SacI fragment including the Ja58 and Ja59 segments of the Ja region of the TCRA locus (according to the sequence reported under the accession number M94081). T-PLL Lec' breakpoint region was ampli®ed from Lec tumoral DNA using primers #1896: 5'-TCCTTACAGATCGT-TAGGT-3' and Ja58: 5'-ACTGTGAGCTGTGTTCCTTC-3' derived from the 0.9HH fragment and the TCRA Ja58 sequences, respectively. The PCR fragment was cloned using the pCR-Script SK + Cloning Kit (Stratagene, La Jolla) and sequenced using the Sequenase 2.0 kit (USBAmersham).
Western blotting
Cell proteins were size fractionated on 10% Tris-tricine SDS-polyacrylamide gels (SchaÈ gger and von Jagow, 1987) , and electrotransferred on nitrocellulose. The membrane was processed as previously described (Madani et al., 1996) . Brie¯y, after an overnight blocking step in 10% non-fat dry milk in PBST (phosphate-buered saline: Tween 20, 0.1%), the antiserum was applied to the membrane for 1 h. The membrane was then washed and incubated with a goat anti rabbit IgG-peroxidase conjugate (Boehringer) for 1 h. After washes, the membrane was overlayed with the chemiluminescent substrate solution and developed according to the manufacturer's instructions (ECL, Amersham). The same membrane was then reprobed using a monoclonal antibody against actin (AB-1, Oncogene Science, Paris) and a sheep anti-mouse peroxidase conjugate (Amersham) to control loading.
RNAse protection assay
Total RNAs were extracted using the acid phenol method (Chomczynski and Sacchi, 1987) , followed if needed by a CsCl cushion ultracentrifugation. RNA protection was done using the RPAII kit following the instructions of the manufacturer (Ambion, Austin, Texas). Two probes were constructed: a 432 bp fragment which corresponds to the XbaI ± HindIII fragment 5' to exon II and a 736 bp fragment from the XbaI site to the junction of exons II/ III. 32 P-labeled antisense RNAs were synthesized using the Riboprobe transcription kit (Promega, Madison, WI). Synthesis of the genomic fragment used as a size marker was done by genomic PCR ampli®cation using oligonucleotides II/III (3'45', at the junction exons II/III): 5'-CTCGTCTCCTCTTCCA-3' and SLICVI (bases 7229 to 7206 from exon II): 5'-TTTAAGAACTCGCGAAACGT-CAG-3'.
